File this under ‘How ironic!’
Martin Shkreli, the pharma bad boy who was vilified for price gouging, apparently alerted the feds to another drug maker that was monopolizing the market for a vital medicine and continually raising its price to sky-high levels. And that other drug maker, Mallinckrodt, has now agreed to pay $100 million to settle antitrust allegations brought by the US Federal Trade Commission.
About the Author Reprints
